However, the combination therapy with A2aR antagonists was effective only when tumors expressed high CD73 levels, suggesting that CD73 can also be used as a potential tumor indicator to assess the benefit of combination therapy (13, 19, 44). This evidence concerns the gene NT5E and neoplasm.